Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
p53
expression was examined in 55 gastric and 107 colorectal carcinomas with an immunoperoxidase technique, using the polyclonal antibody CM1 on routinely fixed, paraffin embedded tissue.
p53 protein
was detected in 47% gastric and in 46% colorectal carcinomas and found to correlate with stage of disease and unfavourable clinical outcome (P less than 0.001). Thus, the proportion of positively reacting neoplasms increased as the stage progressed, tumours which had invaded regional lymph-nodes overexpressed
p53
more frequently than localised carcinomas and an elevated level of
p53
was associated with early relapse and death. In colorectal
carcinoma
p53
positivity was also linked with site and macroscopic configuration of the primary tumour and was most frequently expressed in carcinomas from the rectum and in ulcerative tumours.
p53
overexpression was irrespective of tumour grade. Uniform negative reactivity with anti-
p53
antibody was seen in normal epithelium adjacent to
carcinoma
, intestinal metaplasia, atrophic gastritis and in colonic adenomas. There was a good correlation between immunohistochemical staining on paraffin and frozen sections. These studies suggest that in gastric and colorectal
carcinoma
, immunohistochemical detection of
p53 protein
in routinely fixed tissue can be used along with other established parameters to assess prognostic outcome, especially to identify patients with poor short-term prognosis.
...
PMID:Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. 152 May 94
The molecular genetic alterations in colorectal
carcinoma
are among the best understood of any common human cancer. Identified abnormalities include both dominant-acting oncogenes (ras, myc, src) and suppressor genes which undergo inactivation or deletion (deleted in colorectal carcinoma gene [DCC],
p53
, adenomatous polyposis coli gene [APC], and probably loci on chromosomes 1p and 22q). Accumulation of multiple abnormalities is evident in the adenoma-
carcinoma
sequence with a preferential order, and alteration of DNA methylation is an especially early event. Identification of molecular genetic markers useful for classification and staging of colorectal
carcinoma
is in its infancy. Deletion of the
p53
gene on chromosome 17p, deletion of the DCC gene on 18q, and high fractional allelic loss (fraction of evaluable nonacrocentric autosomal arms with deletion) have been associated with distant metastases and with poorer prognosis in patients without initial evidence of disseminated disease. Additional studies are needed to determine the possible role of these alterations in clinical management.
...
PMID:Molecular genetic alterations as potential prognostic indicators in colorectal carcinoma. 154 Sep
Structural alterations of the
p53
gene were investigated to elucidate the molecular biological difference between superficial and invasive bladder cancer by polymerase chain reaction single-strand conformation polymorphism analysis. In 25 bladder cancers obtained from 23 patients,
p53
gene mutations were investigated in exon regions 4 to 11. Twenty-four were transitional cell carcinomas, and the remaining one was a squamous cell carcinoma. Only one of 13 superficial bladder cancers, including pTis, pTa, and pT1, was found to have
p53
gene mutation. However, of 12 invasive bladder cancers with pT2, pT3, and pT4, six primary carcinomas, including a squamous cell carcinoma and one metastatic
carcinoma
, were found to have
p53
gene mutations. The number of cancers examined in Grades 1, 2, and 3 was three, seven, and 15, respectively.
p53
gene mutation was not found in any of the ten cancers with Grades 1 and 2, while eight of 15 bladder cancers with Grade 3 were found to have
p53
gene mutation. The results indicated that the incidence of
p53
gene mutations appeared to be much higher in invasive-type and high-grade bladder cancers than in superficial and low-grade ones. Our results are compatible with the recently published results by Sidransky et al. [Science (Washington DC), 252: 706-709, 1991] showing that
p53
gene mutations were frequently found in invasive bladder cancers by sequence analysis on polymerase chain reaction amplified products corresponding to exons 5 to 9. Our results are also compatible with previously reported results by Olumi et al. (Cancer Res., 50: 7081-7083, 1990) showing that the loss of chromosome 17p, revealed by analysis with restriction fragment length polymorphism, was frequent in high-grade bladder cancers. In this study,
p53
gene mutations were often found in exon 4 as well as in other exons. Therefore, this region should also be examined for screening of mutations of this gene in bladder cancer. There appeared to be no consistent mutation sites in exons 4 to 11 of the
p53
gene and no specific patterns of the mutation in bladder cancer.
...
PMID:Frequent association of p53 gene mutation in invasive bladder cancer. 154 Sep 47
Expression of
p53
, a tumor-suppressor gene product, was studied immunohistochemically in microwave-fixed, paraffin-embedded sections of 84 colorectal carcinomas and 44 adenomas. Using a monoclonal antibody (PAb1801), nuclear
p53
was detected successfully in 51 of 84 (60.7%) cases of carcinomas, and no stain for
p53
was demonstrated in the adjacent normal mucosa. The results in the microwave-fixed, paraffin-embedded sections correlated with those in the frozen sections. The incidence of
p53
expression in colorectal carcinomas was high in the cases with distant metastasis, but it was not affected by clinicopathologic features such as tumor size or depth of invasion. In colorectal adenomas, only 4 of 44 (9%) adenomas expressed
p53
. This expression of
p53
, however, was restricted to only a few glands within tubular adenomas with mild dysplasia. Thus,
p53 protein
was expressed preferably by malignant tumors of the colorectum. The present study demonstrated the usefulness of microwave fixation to preserve
p53
. The immunohistochemical detection of
p53
in microwave-fixed, paraffin-embedded sections of colorectal
carcinoma
and adenoma can provide valuable information about the mechanism of carcinogenesis in colorectal epithelium.
...
PMID:Immunohistochemical study of p53 expression in microwave-fixed, paraffin-embedded sections of colorectal carcinoma and adenoma. 154 93
Genetic alterations of multiple loci that serve as markers for the induction and progression of disease have been identified in several adenocarcinomas, but not in adenocarcinoma of the prostate. To determine if similar genetic alterations occur in prostate
carcinoma
and could serve as markers for the extent of clinical disease, we have examined 23 predominantly moderately-differentiated, localized prostate carcinomas and one prostatic dysplasia for changes in the structure and copy number of ten selected genes. These genes include 1) those important to androgen metabolism in the prostate, the androgen receptor and steroid 5 alpha reductase genes; 2) those that map to the 10q (PLAU) and 7q (MET) chromosomal regions found deleted in some prostate carcinomas, and 3) proto-oncogenes (ERBB2, INT2, and MYC) and tumor suppressor gene loci (RB1,
TP53
and D17S5) found altered in adenocarcinomas of the breast, colon and lung. Gene alterations were detected in one specimen, a lymph node metastasis from a poorly differentiated tumor. This specimen exhibited loss of heterozygosity for two loci putatively active in tumor suppression,
TP53
and D17S5, on the short arm of chromosome 17. This study indicates that gross genetic alterations were not evident and could not be used as markers of tumor development in well- or moderately-differentiated, localized lesions, but that loss of the 17p region may be a useful marker for advanced carcinomas in the prostate.
...
PMID:Loss of the 17p chromosomal region in a metastatic carcinoma of the prostate. 155 12
Epidermolysis bullosa, a rare genodermatosis, is characterized by increased skin fragility manifest as blistering and sometimes accompanied by scarring. The latter is particularly severe in the recessive dystrophic variant and may be complicated by the development of squamous
carcinoma
in up to 30% of patients. We have studied 23 such tumours in six patients with this variant, with an anti-serum to
p53 protein
. Twenty-six per cent of the squamous carcinomas labelled positively for mutant-type
p53 protein
. This low figure, however, reflects the large number of well-differentiated tumours in this series, where 14 out of 15 were negative. In the moderate to poorly differentiated examples the positivity rate was 63%. Of the three patients in the latter category, one has died from disseminated tumour and another has widespread metastases. The findings support the hypothesis that mutant p53 protein expression correlates with poorer tumour differentiation. They also suggest a possible correlation between
p53 protein
expression and tumour behaviour.
...
PMID:Expression of mutant p53 gene in squamous carcinoma arising in patients with recessive dystrophic epidermolysis bullosa. 156 10
We have investigated the involvement of tumor suppressor genes in the genesis of osteosarcoma by analyzing allele losses at polymorphic loci in tumor tissues. Genotypes of DNA from primary osteosarcoma tissue and corresponding normal cells from 37 patients were analyzed at 58 polymorphic loci representing each autosomal chromosome arm except 5p and 20q. Allele losses were found at polymorphic loci on 36 of 37 chromosome arms analyzed. In particular, four of them showed frequencies of allele loss higher than 60%: 3q (75%); 13q (68%); 17p (72%); and 18q (64%). This result suggests that, in addition to the RB (retinoblastoma) gene on 13q and the
p53
gene on 17p, at least two more tumor suppressor genes located on 3q and 18q are frequently involved in the development of osteosarcoma. The extent of allele losses as defined by fractional allelic loss among 36 tumors was diverse, from 0 to 0.64. The median fractional allelic loss value of 0.32 was much higher than those previously reported in colorectal
carcinoma
and breast
carcinoma
. Although no definite association of fractional allelic loss value to clinical prognosis of each case was found in osteosarcoma, tumors with 17p loss were more prone to the early onset of lung metastasis than tumors without 17p loss, indicating that allele loss on chromosome 17p can be a useful measure of prognosis.
...
PMID:Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. 156 11
The alternatively spliced RNA species of tumor suppressor gene
p53
, containing an additional 96 bases derived from intron 10, is present at approximately 25 to 30% the level of regularly spliced
p53
RNA in both normal epidermal and
carcinoma
cells. The presence of this alternatively spliced RNA in 10T1/2 fibroblast cells, mouse liver and testis suggests that this alternative splicing may be universal. The level of alternatively spliced
p53
RNA was increased coordinately with that of regularly spliced
p53
in 10T1/2 cells in response to epidermal growth factor. Immunoprecipitation analysis of epidermal cells using monoclonal antibodies which recognize different epitopes of
p53
suggested that distinct
p53
proteins may be translated from both RNA species. Considering previous observations on the potential importance of carboxyl terminal sequences in
p53
function, knowledge of the ubiquitous presence of alternatively spliced
p53
is important for future studies of
p53
function in normal cells and in oncogenesis.
...
PMID:Alternatively spliced p53 RNA in transformed and normal cells of different tissue types. 157
The constant denaturant gel electrophoresis technique was used to screen for
TP53
germ line mutations in 237 women with breast
carcinoma
(167 unselected patients, 30 patients with at least one first-degree relative with breast cancer, and 40 women diagnosed with breast cancer before age 35). A germ line mutation at codon 181 was noted in one of the unselected patients and a codon 245 mutation in one of the early-onset patients. Both had a family history of breast cancer and other malignancies suggestive of Li-Fraumeni syndrome. The codon 245 mutation was also present in this patient's affected mother.
...
PMID:Screening for germ line TP53 mutations in breast cancer patients. 159 32
The molecular pathology of human pancreatic cancer is poorly understood, particularly with regard to the role of known tumor-suppressor genes. We have examined the expression of the
p53
and Rb-1 tumor-suppressor genes in seven human pancreatic
carcinoma
cell lines and 10 primary pancreatic carcinomas. Examination of the Rb-1 gene by Northern hybridization and immunoprecipitation analyses revealed the absence of Rb-1 protein expression in two cell lines. Moreover, regions of absent nuclear staining in two primary pancreatic carcinomas were detected by immunohistochemical analysis. Investigation of
p53
by Southern, Northern, immunohistochemical and immunoprecipitation analyses revealed multiple abnormalities, including gross rearrangements in two cell lines, the absence of detectable
p53
transcript in two cell lines and a truncated transcript in one line. Six cell lines overexpressed
p53 protein
, while one line revealed the absence of
p53
product by immunohistochemical and immunoprecipitation analyses. Sequence analysis of exons 5-8 of the
p53
gene confirmed these analyses, revealing missense mutations in all seven cell lines in codons 181, 220, 248, 249, 265, 272 and 273. Of 10 mutations identified, nine were transitions and 50% were in codon 273. Immunohistochemical analyses of frozen primary pancreatic carcinomas revealed positive nuclear staining for
p53
in 40% of cases. Mutations were identified in codons 238 and 286 and in intron 9 in several representative specimens. Alterations in the
p53
and Rb-1 genes may be important features in the development of human pancreatic cancer.
...
PMID:Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. 163 Aug 14
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>